Procept Biorobotics vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Procept Biorobotics Corp (PRCT)

Q3 202624 Jul – 5 Aug 2026

▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.
This is the most direct new fundamental negative for PRCT's demand outlook.
Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.
This is a new legal/regulatory overhang that directly pressures PRCT shares.
Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.
This shows the mixed financial picture: revenue growth is positive but losses continue.
HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.
This highlights the company's plan to offset legacy weakness and reach profitability.

July 202624 Jul – 5 Aug 2026

▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.
This is the most direct new fundamental negative for PRCT's demand outlook.
Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.
This is a new legal/regulatory overhang that directly pressures PRCT shares.
Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.
This shows the mixed financial picture: revenue growth is positive but losses continue.
HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.
This highlights the company's plan to offset legacy weakness and reach profitability.

Latest24 Jul – 5 Aug 2026

▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.
This is the most direct new fundamental negative for PRCT's demand outlook.
Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.
This is a new legal/regulatory overhang that directly pressures PRCT shares.
Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.
This shows the mixed financial picture: revenue growth is positive but losses continue.
HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.
This highlights the company's plan to offset legacy weakness and reach profitability.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.